Friday, 10 August 2012

Vardenafil Hydrochloride


Class: Phosphodiesterase Inhibitors
VA Class: GU900
Chemical Name: 1 - [[3 - (3,4 - Dihydro - 5 - methyl - 4 - oxo - 7 - propylimidazo[5,1 - f] - as - triazin - 2 - yl) - 4 - ethoxyphenyl]sulfonyl] - 4 - ethylpiperazine
Molecular Formula: C23H32N6O4S
CAS Number: 224785-90-4
Brands: Levitra


Special Alerts:


[Posted 10/18/2007] FDA informed healthcare professionals of reports of sudden decreases or loss of hearing following the use of PDE5 inhibitors sildenafil (Viagra), tadalafil (Levitra), vardenafil (Cialis) for the treatment of erectile dysfunction, and sildenafil (Revatio) for the treatment of pulmonary arterial hypertension. In some cases, the sudden hearing loss was accompanied by tinnitus and dizziness. Medical follow-up on these reports was often limited which makes it difficult to determine if the loss of hearing was related to the use of one of the drugs, an underlying medical condition or other risk factors for hearing loss, a combination of these factors or other factors. The PRECAUTIONS and ADVERSE REACTIONS sections of the approved product labeling for sildenafil (Viagra), tadalafil, and vardenafil were revised. FDA is working with the manufacturer to revise the labeling for sildenafil (Revatio). For more information visit the FDA website at: , and .



Introduction

Vasodilating agent; a selective phosphodiesterase (PDE) inhibitor.1


Uses for Vardenafil Hydrochloride


Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.


Erectile Dysfunction


To facilitate attainment of a sexually functional erection in males with erectile dysfunction (ED, impotence).1


Vardenafil Hydrochloride Dosage and Administration


General



  • Dosage must be individualized carefully according to the patient’s tolerance and erectile response.1




  • Sexual stimulation is required for response to therapy.1



Administration


Oral Administration


Administer orally, no more than once daily, without regard to meals.1 3


Administer approximately 1 hour before anticipated sexual activity.1


Dosage


Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.


Available as vardenafil hydrochloride; dosage expressed in terms of vardenafil.1


Adults


Erectile Dysfunction

Oral

Initially, 10 mg.1 Depending on effectiveness and tolerance, increase dosage to a maximum of 20 mg or decrease to 5 mg. Administer no more frequently than once daily.1


Prescribing Limits


Adults


Erectile Dysfunction

Oral

Maximum 20 mg daily.1


Special Populations


Hepatic Impairment


In patients with moderate hepatic impairment (Child-Pugh class B), decrease initial dosage to 5 mg; maximum dosage is 10 mg once daily.1 Not studied in patients with severe hepatic impairment (Child-Pugh class C).1


Renal Impairment


Dosage adjustments not required in patients with patients with mild (Clcr of 50–80 mL/minute) to severe (Clcr <30 mL/minute) renal impairment.1 Not studied in patients requiring renal dialysis.1


Geriatric Patients


Reduce initial dose to 5 mg given no more frequently than once daily in men ≥65 years of age.1 26


Cautions for Vardenafil Hydrochloride


Contraindications



  • Known hypersensitivity to vardenafil or any ingredient in the formulation.1




  • Concomitant use of nitrates, nitrites, or nitric oxide donors, either regularly or intermittently, or α-adrenergic blocking agents.1 28




  • Should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status.1 5



Warnings/Precautions


Warnings


Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.


Cardiovascular Effects

Serious, potentially fatal cardiovascular events reported rarely.1 5 6


Use not recommended in patients with a recent (within 6 months) MI, stroke, or life-threatening arrhythmia; resting hypotension (<90 mm Hg resting SBP) or hypertension (170/110 mm Hg SBP/DBP); or severe heart failure or unstable angina.1 4 7 8 26


Possible hypotension; consider whether patients with underlying cardiovascular disease could be affected adversely by vardenafil’s vasodilatory activity.1 Risk of an undesired hypotensive or vasodilatory response is of particular concern in patients with left-ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis).1 6


Potentiation of hypotensive effect with organic nitrates may result in life-threatening hypotension and/or hemodynamic compromise.1 Possible significant hypotension when given concurrently with α-adrenergic blocking agents.1 Manufacturers state that concomitant use of nitrates or α-adrenergic blocking agents with vardenafil is contraindicated.1 (See Specific Drugs under Interactions.)


Possible prolonged QT interval.1 Use not recommended in patients with known prolongation of the QT interval and those receiving class IA (e.g., quinidine, procainamide) or class III (e.g., amiodarone, sotalol) antiarrhythmic agents.1


Concomitant Use with Potent CYP3A4 Inhibitors

Safety not established with long-term use of vardenafil concomitantly with potent CYP3A4 inhibitors (e.g., ritonavir, indinavir, ketoconazole, itraconazole).1 Increased plasma vardenafil concentrations with concomitant use; dosage reduction of vardenafil recommended.1 (See Specific Drugs under Interactions.)


Priapism

Possible prolonged erections (>4 hours in duration) and priapism (painful erection >6 hours).1


May result in penile tissue damage and permanent loss of potency if priapism is not treated immediately.1 Use with caution in patients with conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia).1


Ocular Effects

Possible visual disturbances (e.g., abnormal, dim, or blurred vision; changes in color vision [e.g., chromatopsia]).1 4


Not studied in patients with hereditary degenerative retinal disorders, including those with retinitis pigmentosa.1 Use not recommended until further information is available.1


Sensitivity Reactions


Anaphylactic reaction, including laryngeal edema, reported.1


General Precautions


Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.


Patient Assessment

Thorough medical history and physical examination recommended to diagnose erectile dysfunction, determine potential underlying causes, and identify appropriate treatment.1 5


Review of the patient’s current drug regimens recommended to detect possible drug-induced erectile dysfunction.5


Hematologic Effects

No prolongation of bleeding time with vardenafil dosages ≤20 mg.1


However, not studied in patients with bleeding disorders or active peptic ulcers;1 4 8 therefore, careful risk/benefit assessment is necessary before use in such patients.1 4 8


GU Effects

Use with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie’s disease).1


Specific Populations


Pregnancy

Category B.1 Not indicated for use in women.1


Lactation

Not indicated for use in women.1


Pediatric Use

Not indicated for use in neonates or children.1


Geriatric Use

Safety and efficacy in males ≥65 years of age similar to that in younger males.1 Increased plasma vardenafil concentrations in men ≥65 years of age compared to that in younger males; therefore consider lower initial dosage.1 (See Geriatric Patients under Dosage and Administration.)


Hepatic Impairment

Decreased clearance in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.1 (See Hepatic Impairment under Dosage and Administration.) Not studied in patients with severe hepatic impairment (Child-Pugh class C), and use of the drug in such patients is not recommended.1 26


Renal Impairment

Clearance decreased in patients with moderate (Clcr 30–50 mL/minute) to severe (Clcr <30 mL/minute) renal impairment.1 (See Renal Impairment under Dosage and Administration.) Not studied in patients with end-stage renal disease requiring dialysis.1


Common Adverse Effects


Headache,1 2 7 8 flushing, 1 2 7 8 rhinitis,1 2 8 dyspepsia.1 2 7


Interactions for Vardenafil Hydrochloride


Metabolized principally by CYP3A4; CYP2C and CYP3A5 appear to play a minor role.1


Drugs Affecting Hepatic Microsomal Enzymes


Inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased plasma vardenafil concentrations).1


Specific Drugs































































Drug



Interaction



Comments



α-Adrenergic blocking agents



Possible symptomatic hypotension 1



Concurrent use is contraindicated1



Alcohol



No potentiation of hypotensive effect reported1



Antacids (aluminum hydroxide and magnesium hydroxide)



Pharmacokinetic interaction unlikely1



Antiarrhythmic agents (amiodarone, procainamide, quinidine, sotalol)



Possible prolongation of the QTc interval1



Avoid concomitant use1



Antihypertensive agents



Possible additive hypotensive effects



Antiretroviral agents, HIV protease inhibitors



Possible increased vardenafil concentrations and increased risk of vardenafil-associated adverse effects (e.g., hypotension, visual changes, prolonged erection)1 29 31 33


Decreased indinavir and ritonavir concentrations1 29 31 33



Ritonavir or lopinavir: Do not exceed a single vardenafil dose of 2.5 mg in 72 hours;1 29 no change in ritonavir dosage needed29


Ritonavir in combination with indinavir, atazanavir, saquinavir, fosamprenavir, or nelfinavir: Do not exceed a vardenafil dosage of 2.5 mg in 72 hours29 33


Nelfinavir, indinavir, amprenavir, saquinavir, fosamprenavir, or atazanavir: Use initial vardenafil dosage of 2.5 mg and do not exceed a single dose of 2.5 mg in 24 hours1 29 30 31 33


Monitor closely 29 31 32 33 34



Antiretroviral agents, nonnucleoside reverse transcriptase inhibitors



Possible increased vardenafil concentrations and increased risk of vardenafil-associated adverse effects (e.g., hypotension, visual changes, prolonged erection)29



Delavirdine: Use initial vardenafil dosage of 2.5 mg; do not exceed 2.5 mg once in 24 hours29



Aspirin



No increase in bleeding time reported1



Cimetidine



Pharmacokinetic interaction unlikely1



Digoxin



Pharmacokinetic interaction unlikely1



Erythromycin



Increased AUC and peak plasma concentrations of vardenafil1



Reduce initial vardenafil dosage to 5 mg in patients receiving erythromycin1



Glyburide



Pharmacokinetic interaction unlikely1



Inhaled nitrites (e.g., amyl or butyl nitrite)



Potentiation of hypotensive effect28



Concomitant use is contraindicated28 (see Cautions)



Itraconazole



Possible increased vardenafil concentrations1



Reduce initial vardenafil dosage to 2.5 mg in patients receiving itraconazole 400 mg daily1


Reduce initial vardenafil dosage to 5 mg in patients receiving itraconazole 200 mg daily1



Ketoconazole



Increased vardenafil concentrations 1



Reduce initial vardenafil dosage to 2.5 mg in patients in patients receiving ketoconazole 400 mg daily1


Reduce initial vardenafil dosage to 5 mg in patients receiving ketoconazole 200 mg daily1



Nifedipine



Possible additive hypotensive effect1



Nitrates and nitric acid donors



Potentiation of vasodilatory effects; potentially life-threatening hypotension and/or hemodynamic compromise can result1



Concomitant use is contraindicated1 28



Ranitidine



Pharmacokinetic interaction unlikely



Warfarin



Pharmacokinetic and pharmacodynamic interaction unlikely1


Vardenafil Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Rapidly absorbed following oral administration; peak concentrations usually attained within 0.5–2 hours.1


Absolute bioavailability is approximately 15%.1


Food


Administration with a high-fat meal reduces the peak plasma concentrations by 18–50%.1 3


Distribution


Extent


Extensively distributed into tissues.1


Plasma Protein Binding


Approximately 95% for the drug and major metabolite.1


Elimination


Metabolism


Metabolized in the liver to active metabolite(s) principally via CYP3A4, with minor contributions from CYP3A5 and CYP2C.1


Elimination Route


Excreted as metabolites principally in the feces (91–95%) and to a lesser extent in urine (2–6%).1


Half-life


Terminal half-life 4–5 hours for drug and major metabolite.1


Special Populations


Clearance reduced in men ≥65 years of age, resulting in an increase in AUC and peak plasma concentrations compared with younger males.1


Clearance reduced in patients with moderate (Clcr of 30–50 mL/minute) or severe (Clcr <30 ml/minute) renal impairment, resulting in an increase in AUC compared with patients with normal renal function.1


Clearance reduced in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment, resulting in an increase in AUC and peak plasma concentrations compared with healthy adults.1


Stability


Storage


Oral


Tablets

25°C (may be exposed to 15–30°C).1


ActionsActions



  • Selective inhibitor of phosphodiesterases (PDEs) with the greatest selectivity for PDE type 5, the principal isoenzyme involved in the metabolism of cGMP to GMP in the corpora cavernosa of the penis.1




  • Enhances the effect of nitric oxide by inhibiting PDE type 5-mediated hydrolysis of cGMP.1 2




  • Potentiates accumulation of cGMP only when cGMP production in the penis is increased by sexual arousal.1 No effect on erectile function in the absence of sexual stimulation.1




  • Modest peripheral vasodilation accompanied by a small increase in heart rate at usual dosages.1 6 27




  • Although less affinity than sildenafil for PDE type 6 receptor in the retina, some transient visual abnormalities observed.1 27



Advice to Patients


Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.



  • Importance of informing clinician of risk factors for cardiovascular disease prior to initiating any treatment for erectile dysfunction.1 5




  • Importance of informing clinician of stroke history.1




  • Importance of informing clinician of low or high BP.1




  • Importance of informing clinician of the presence of retinitis pigmentosa.2




  • Importance of informing patients of the potential for life-threatening hypotension and/or hemodynamic compromise with concurrent use of organic nitrates and nitrites (e.g., nitroglycerin, isosorbide dinitrate) or nitric oxide donors (e.g., sodium nitroprusside) in any form, including the recreational use of inhaled nitrites (“poppers”), because of the potential for hypotension and associated dizziness, syncope, or even MI or stroke.1 26




  • Importance of avoiding concurrent use of α-adrenergic blocking agents because of the potential for hypotension, dizziness, or fainting.1




  • Importance of seeking immediate medical attention if an erection persists >4 hours or is painful.1




  • Importance of advising patient that vardenafil does not protect against sexually transmitted diseases (e.g., HIV) and about measures to protect against such transmission.1




  • Importance of contacting a clinician for assessment of therapeutic benefit, the need for possible dosage adjustment, and potential adverse effects.1




  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.




























Vardenafil Hydrochloride

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, film-coated



2.5 mg (of vardenafil)



Levitra



Schering-Plough



5 mg (of vardenafil)



Levitra



Schering-Plough



10 mg (of vardenafil)



Levitra



Schering-Plough



20 mg (of vardenafil)



Levitra



Schering-Plough


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Levitra 10MG Tablets (SCHERING): 10/$163.99 or 30/$469.97


Levitra 20MG Tablets (SCHERING): 10/$163.99 or 30/$469.97


Levitra 5MG Tablets (SCHERING): 10/$163.99 or 30/$469.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions November 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Schering-Plough. Levitra (vardenafil hydrochloride) tablets prescribing information. West Haven, CT; 2004 Oct.



2. Coleman CI, Carabino JM, Vergara CM. Vardenafil: an oral selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Formulary. 2003; 38:131-148.



3. Rajagopalan P, Mazzu A, Xia C et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003; 43(3):260-7. [IDIS 495567] [PubMed 12638394]



4. Brock G, Nehra A, Lipshultz LI et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003; 170(4 Pt 1):1278-83. [IDIS 504241] [PubMed 14501741]



5. Jackson G, Betteridge J, Dean J et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement--update 2002. Int J Clin Pract. 2002; 56(9):663-71. [IDIS 491098] [PubMed 12469980]



6. Cheitkin MD, Hutter AM, Brindis RG for the American College or Cardiology and American Heart Association. Technology and Practice Executive Committee [duplicate publication of Cheitkin MD, Hutter AM, Brindis RG for the American College or Cardiology and American Heart Association. ACC/AHA expert consensus document: use of sildenafil (viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999; 33:273-82. [IDIS 426556] [PubMed 9935041]



7. Hellstrom WJ, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003; 61(4 Suppl 1):8-14. [PubMed 12657355]



8. Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003; 26(3):777-83. [IDIS 517794] [PubMed 12610037]



9. National Institutes of Health Office of Medical Applications of Research. Consensus Conference: impotence. JAMA. 1993; 270:83-90. [IDIS 316686] [PubMed 8510302]



10. Pfizer Inc, New York, NY: Personal communication on sildenafil.



11. Reviewers’ comments on sildenafil (personal observations).



12. The Process of Care Consensus Panel. Position paper: the process of care model for evaluation and treatment of erectile dysfunction. Int J Impotence Res. 1999; 11:59-70.



13. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol. 1999; 10:1381-8. [PubMed 10361878]



14. Guay AT, Nankin AR et al. AACE clinical practice guidelines for the evaluation and treatment of male sexual dysfunction. From American Association of Clinical Endocrinologists web site. ()



15. Whitehead ED, Klyde BJ, Zussman S et al. Treatment alternatives for impotence. Postgrad Med. 1990; 88:139-52. [IDIS 269901] [PubMed 2199954]



16. Gerber GS, Levine LA. Pharmacological erection program using prostaglandin E1. J Urol. 1991; 146:786-9. [IDIS 287641] [PubMed 1875494]



17. Porst H. Editorial comments on the process of care model for evaluation and treatment of erectile dysfunction. Int J Impotence Res. 1999; 11: 72-3.



18. Sarramon JP. Editorial comments on the process of care model for evaluation and treatment of erectile dysfunction. Int J Impotence Res. 1999; 11:73.



19. Vermeuler A. Editorial comments on the process of care model for evaluation and treatment of erectile dysfunction. Int J Impotence Res. 1999; 11:74.



20. Sohn MHH. Editorial comments on the process of care model for evaluation and treatment of erectile dysfunction. Int J Impotence Res. 1999; 11:72.



21. Sefetl AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004; 27(Suppl. 1):I-14-9.



22. Padma-Nathan H. A new era in the treatment of erectile dysfunction. Am J Cardiol. 1999; 84:18-23N. [PubMed 10404845]



23. Wespes E, Amar E, Hatzichtistou D et al. Guidelines on reactile dysfunction. Arnhem: European Association of Urology, 2004 Mar. Available at . Accessed 2004 Aug.



24. Pfizer Inc. Viagra (sildenafil citrate) prescribing information. New York, NY; 2002 Sep.



25. Lilly ICOS. Cialis (tadalafil) tablets prescribing information. Indianapolis, IN; 2003 Nov.



26. Schering-Plough, Kenilowrth, NJ. Personal communication.



27. Crowe SM, Streetman DS. Vardenafil treatment for erectile dysfunction. Ann Pharmacother. 2004; 38:77-85. [IDIS 514325] [PubMed 14742800]



28. Schering-Plough. Levitra (vardenafil hydrochloride) tablets patient information. From Levitra website: (). Accessed 2005 May16.



29. Panel on Clinical Practices for Treatment of HIV infection of the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (Apr 7, 2005). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website ().



30. Merck & Company Inc. Crixivan (indinavir sulfate) capsules prescribing information. West Point, PA; 2004 May.



31. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) prescribing information. Princeton, NJ; 2004 Jul.



32. Roche Pharmaceuticals. Fortovase (saquinavir) soft gelatin capsules prescribing information. Nutley, NJ; 2003 Dec.



33. GlaxoSmithKline. Lexiva (fosamprenavir calcium) tablets prescribing information. Research Triangle Park, NC; 2004 May.



34. Roche Laboratories. Invirase (saquinavir mesylate) capsules prescribing information. Nutley, NJ; 2004 Dec.



More Vardenafil Hydrochloride resources


  • Vardenafil Hydrochloride Side Effects (in more detail)
  • Vardenafil Hydrochloride Dosage
  • Vardenafil Hydrochloride Use in Pregnancy & Breastfeeding
  • Vardenafil Hydrochloride Drug Interactions
  • Vardenafil Hydrochloride Support Group
  • 45 Reviews for Vardenafil Hydrochloride - Add your own review/rating


Compare Vardenafil Hydrochloride with other medications


  • Erectile Dysfunction

Tuesday, 7 August 2012

Iprivask




In the US, Iprivask (desirudin systemic) is a member of the drug class thrombin inhibitors and is used to treat Deep Vein Thrombosis, Prophylaxis.

US matches:

  • Iprivask

Ingredient matches for Iprivask



Desirudin

Desirudin is reported as an ingredient of Iprivask in the following countries:


  • United States

International Drug Name Search

Saturday, 4 August 2012

Chromitope





Dosage Form: injection
Chromitope® Sodium

Sodium Chromate Cr 51 Injection USP

Chromitope Description


Chromitope Sodium (Sodium Chromate Cr 51 Injection USP) is a diagnostic radiopharmaceutical for intravenous administration. This agent provides radioactive chromium 51 in the form of sterile, nonpyrogenic aqueous solution of sodium chromate (Na2  51CrO4). The solution also contains 6 mg/mL benzyl alcohol as a preservative and sodium chloride for isotonicity; the pH has been adjusted to 7.5–8.5 with hydrochloric acid or sodium bicarbonate.



PHYSICAL CHARACTERISTICS


Chromium 51 decays by electron capture and gamma emission with a physical half-life of 27.7 days.1 The principal photon that is useful for detection and imaging studies is listed in Table 1.










Table 1
Principal Radiation Emission Data
RadiationMean % per

Disintegration
Mean Energy

(keV)
Gamma-19.83320.1

1Kocher, David, C., “Radioactive Decay Data Tables”, DOE/TIC-11026, (1981) p. 74.

External Radiation


The specific gamma ray constant for Cr 51 is 0.19 R/hour-millicurie at 1 cm. The first half-value layer is 0.20 cm lead (Pb). Values for the relative attenuation of the radiation emitted by the radionuclide that result from interposition of two thicknesses of Pb are shown in Table 2. To facilitate control of the radiation exposure from millicurie amounts of this radionuclide, the use of a 0.60 cm thickness of lead will attenuate the radiation emitted by a factor of about 10.










Table 2
Radiation Attenuation by Lead Shielding
Shield Thickness

(Pb) cm
Attenuation

Factor
0.200.5
0.6010-1

To correct for physical decay of CR 51, the fractions that remain at selected intervals before and after the time of calibration are shown in Table 3.





















































Table 3
Physical Decay Chart: Cr 51 half-life 27.7 days
*Calibration time
DaysFraction

Remaining
DaysFraction

Remaining
DaysFraction

Remaining
0*1.000250.535600.223
10.975300.472650.197
20.975350.417700.173
40.905400.368750.153
80.819450.324800.135
150.687500.286850.119
200.606550.253

Chromitope - Clinical Pharmacology


The chromium in this agent is present as the dianionic chromate ion in which form it appears to bind to the red blood cell in two steps, initially by a rapid but reversible attachment to the cell membrane followed by a slower nearly irreversible binding to intracellular hemoglobin and reduction to the anionic state. It has been suggested that the slow rate of uptake is dependent on the rate at which chromate can penetrate the cell membrane. Binding is maintained until the red blood cells are sequestered by the spleen or until elution of the chromium occurs into the plasma. The chromium is then readily excreted mainly in the urine. Once liberated by elution or erythrocyte senescence, chromium 51 is not available for relabeling of red cells.


In normal individuals the erythrocyte survival half-time (T ½) as measured by the chromium 51 “random labeling” technique, generally ranges between 25 and 35 days. This apparent short survival time, when compared to the 120 day life span of the red blood cells, is due to the elution of chromium from the cells and to cell damage that probably occurs during the process of withdrawing them from the body and labeling. Subnormal T 1/2 may be indicative of blood loss, sequestration of red blood cells by the spleen, or shortened cell viability, as occurs in hemolytic anemia.



Indications and Usage for Chromitope


Chromitope Sodium (Sodium Chromate Cr 51 Injection USP) is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss.



Contraindications


None known.



Precautions



General


In the use of any radioactive material, care should be taken to insure minimum radiation exposure to the patient and occupational workers consistent with proper patient management.


Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labeling. A system of checks similar to the ones used for administering blood transfusions should be routine.


In order to obviate or minimize the possibility of contamination and of increased fragility of the labeled red blood cells, sterile techniques should be employed throughout the collection, labeling, rinsing, suspending, and injection of red blood cells. In addition, the number of washes and transfers should be kept to a minimum and only sterile, non-pyrogenic isotonic diluent should be employed throughout the labeling procedure.


Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential, or whether this agent may impair fertility in males or females.


Pregnancy: Teratogenic Effects

Category C


Animal reproduction studies have not been conducted with Sodium Chromate Cr 51 Injection. It is also not known whether this agent can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. A suspension of chromium 51-labeled red blood cells containing Sodium Chromate Cr 51 Injection and Bracco A-C-D Solution Modified (Anticoagulant Citrate Dextrose Solution Modified) should be administered to a pregnant woman only if clearly needed.


Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.



Nursing Mothers


Caution should be exercised when Sodium Chromate Cr 51 Injection is administered to a nursing woman since chromium 51 is excreted in human milk during lactation. Therefore, formula feedings should be substituted for breast feedings.



Pediatric Use


Safety of the chromium 51-labeled suspension of red blood cells in children has not been established.



Adverse Reactions


No adverse reactions specifically attributable to Sodium Chromate Cr 51 Injection have been reported.



Chromitope Dosage and Administration


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.


The usual doses to the average patient (70 kg) are as follows: Determination of red blood cell volume or mass–0.37 to 1.11 megabecquerels (10 to 30 microcuries).


Study of red blood cell survival time–5.55 megabecquerels (150 microcuries).


Evaluation of blood loss–7.40 megabecquerels (200 microcuries).


The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.


The specific activity should be not less than 370 megabecquerels (10 millicuries) per mg [0.37 megabequerels (10 microcuries) per µg] of Sodium Chromate at the time of use.


It is essential that the user adhere to strict aseptic procedures during the preparation, withdrawal and administration of the labeled red blood cells. Waterproof gloves are to be worn during the labeling procedure to prevent the possibility of radioactive contamination of the hands. Shielded syringes should be used when adding the Chromitope Sodium to the reaction vial and for the withdrawal and administration of the labeled red blood cells. To maintain adequate shielding during the life of the labeled preparation, a lead vial shield and lead cover must remain in place on the reaction vial.



Red Blood Cell Labeling Procedure


Labeling may be performed without washing or centrifugation steps directly in the silicone-coated reaction vial of Bracco A-C-D Solution Modified.*


*Anticoagulant Acid Citrate Dextrose Solution Modified containing the same ingredients as Anticoagulant Citrate Dextrose Solution USP but in different ratio (see package insert for complete details). Bracco A-C-D Solution Modified is supplied as 10 mL of sterile, nonpyrogenic solution in convenient silicone-coated 75 mL capacity reaction vials.


A 30 to 50 mL sample of whole blood is withdrawn from the patient and added aseptically to a vial of Bracco A-C-D Solution Modified. 1.85 to 5.55 megabecquerels (50 to 150 microcuries) of Chromitope Sodium (Sodium Chromate Cr 51 Injection USP) is then injected into the reaction vial using a shielded syringe. The amount of radioactivity added to the vial will depend on the intended use of the labeled red blood cells. The suspension is incubated for 30 to 60 minutes at room temperature with frequent gentle agitation. After incubation, 100 mg Ascorbic Acid Injection USP is injected into the vial. The ascorbic acid reduces any remaining unbound dianionic chromium 51 to the anionic state which does not penetrate red blood cells; thus in vivo labeling of red blood cells is prevented.


The extent of chromium 51 labeling is influenced by hematocrit values; hematocrits below 35 percent will result in a higher degree of labeling, whereas hematocrits exceeding 45 percent will produce the opposite result. Although the rate of labeling is initially more rapid at 37° C, samples incubated at 37° C and room temperature will show the same degree of chromium 51 labeling after a 30-minute period.


Labeling may also be accomplished by centrifugation and washing techniques which are described in the literature.


The admixture of Sodium Chromate Cr 51 Injection with Bracco A-C-D Solution Modified (Anticoagulant Citrate Dextrose Solution Modified) for use as a stock solution is not recommended. For best results, the whole blood sample should be combined with Bracco A-C-D Solution Modified prior to labeling.



Radiation Dosimetry


The estimated absorbed radiation doses to an average patient (70 kg) following an intravenous injection of 7.40 megabecquerels (200 microcuries) of Cr 51 are shown in Table 4.























Table 4
Estimated Absorbed Radiation Doses
Method of Calculation: A Schema for Absorbed-Dose Calculations for Biologically Distributed Radionuclides, MIRD Pamphlet No. 1. J Nucl Med Suppl 1:7, 1968
TissuemGy/

7.40 MBq
rads/

200 µCi
Blood 2.00.20
Spleen26.42.64
Testes0.660.066
Ovaries0.660.066
Whole body0.550.055

How is Chromitope Supplied


Chromitope Sodium (Sodium Chromate Cr 51 Injection USP) is available in multiple dose vials containing 9.25 megabecquerels (250 microcuries) (1.25 mL) and 37 megabecquerels (1.0 millicurie) (5.0 mL) at the time of calibration. Complete assay data for each vial are provided on the container.



Storage


Store the product as supplied at 20-25 °C (68-77 °F) [See USP]; avoid excess heat.



Disposal


Any unused portion of the labeled preparation must be stored and disposed of in accordance with the conditions of NRC radioactive material license pursuant to Agreement State Regulation.


The U.S. Nuclear Regulatory Commission has approved this prepared radiopharmaceutical for distribution to persons licensed to use byproduct material identified in §35.100 of 10 CFR Part 35, to persons who hold an equivalent license issued by an Agreement State, and, outside the United States, to persons authorized by the appropriate authority.



Manufactured for

Bracco Diagnostics Inc.

Princeton, NJ 08543

by GE Healthcare Limited

Little Chalfont, England


Revised August 2005

S/4669/03













Chromitope SODIUM 
sodium chromate, cr 51  injection, solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0270-0059
Route of AdministrationINTRAVENOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
SODIUM CHROMATE CR-51 (chromate ion CR-51)SODIUM CHROMATE CR-51.2 mCi  in 1 mL






Inactive Ingredients
Ingredient NameStrength
Benzyl alcohol6 mg  in 1 mL


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10270-0059-205 mL In 1 VIALNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01399312/27/1971


Labeler - BRACCO DIAGNOSTICS INC. (849234661)

Registrant - BRACCO DIAGNOSTICS INC. (849234661)









Establishment
NameAddressID/FEIOperations
GE HEALTHCARE LTD217152818MANUFACTURE
Revised: 01/2010BRACCO DIAGNOSTICS INC.

More Chromitope resources


  • Chromitope Side Effects (in more detail)
  • Chromitope Dosage
  • Chromitope Support Group
  • 0 Reviews · Be the first to review/rate this drug

Pulvinal Salbutamol Inhaler 200 micrograms





1. Name Of The Medicinal Product



Pulvinal® Salbutamol 200 micrograms/metered dose inhalation powder.


2. Qualitative And Quantitative Composition



Each actuation provides salbutamol 200 micrograms (metered dose) or 188 micrograms as emitted dose.



For excipients, see 6.1.



3. Pharmaceutical Form



Inhalation powder administered from a multidose powder inhaler.



4. Clinical Particulars



4.1 Therapeutic Indications



Pulvinal Salbutamol is indicated for the relief of symptoms of asthma, bronchospasm and/or reversible airways obstruction and for the prevention of exercise-and allergen-induced asthma.



Pulvinal Salbutamol is particularly suitable for the relief of symptoms in mild, moderate and severe asthma.



The use of an inhaled β2-agonist must not delay the introduction of regular inhaled corticosteroid therapy.



4.2 Posology And Method Of Administration



Pulvinal Salbutamol is for inhalation use only.



Each inhalation of Pulvinal Salbutamol provides 200 micrograms of salbutamol.



Adults:



For the relief of asthma symptoms, including acute bronchospasm, and for managing intermittent episodes of asthma, one inhalation should be administered.



For prevention of exercise-or allergen-induced asthmatic symptoms, one inhalation should be taken 10-15 minutes before challenge.



There is no need to adjust the dosage in elderly patients.



Children aged above 6 years:



One inhalation for the relief of asthma symptoms, including acute bronchospasm, for the management of episodic asthma, or 10-15 minutes before allergen exposure or exercise.



Use of Pulvinal Salbutamol should not exceed four inhalations (i.e. 800 micrograms) in 24 hours.



The bronchodilator effect of salbutamol lasts for a minimum of 4 hours, except in those patients whose asthma is worsening. Patients should be warned not to increase the dosage and to seek medical advice in case of worsening of their asthma symptoms. Frequent supplementary use of salbutamol or a sudden increase in dose is likely to indicate poorly controlled or deteriorating asthma.



Instructions for use –



Do not remove the cap protecting the inhaler until the moment of use.



Unscrew the protective cap and before twisting the inhaler, hold it upright and tap it gently against a hard surface to level the powder in the chamber.



Holding the inhaler upright press the blue button on the mouth piece and rotate the inhaler body anti-clockwise until the red mark on the body shows through the hole in the mouthpiece (dose-loading position).



While still holding the inhaler upright, rotate the inhaler body clockwise until the green mark on the body shows through the hole in the mouthpiece (dose-delivery position).



Breathe out deeply. While still holding the inhaler upright put the mouthpiece between your lips and breathe in through your mouth. Hold your breath for a few seconds.



To obtain full therapeutic benefit, it is essential that the patient follows the instructions for use (see patient information leaflet) carefully.



4.3 Contraindications



Pulvinal Salbutamol is contra-indicated in patients with a history of hypersensitivity to either salbutamol or lactose (see Section 4.4. below).



Inhaled salbutamol preparations are not appropriate in the management of premature labour and in threatened abortion.



4.4 Special Warnings And Precautions For Use



The dosage and frequency of administration of inhaled salbutamol should only be increased on medical advice. If a previously effective dose of Pulvinal Salbutamol fails to provide relief lasting for a minimum of three hours, or in the event of increased use of the product, the patient should be advised to seek medical advice, as this may be indicative of deteriorating asthma. In situations where asthma control may appear to be deteriorating, patients should be re-assessed and consideration given to increasing anti-inflammatory therapy.



Patients with severe or unstable asthma are at risk of acute severe episodes and even death and should not be treated only or mainly with bronchodilators. Such patients may require regular medical assessment, including lung function testing, and may require treatment with the maximum recommended dose of inhaled corticosteroids and/or with oral corticosteroids.



Severe exacerbations of asthma must be treated in the usual way.



Salbutamol should be administered cautiously in patients affected by thyrotoxicosis. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Salbutamol should not be administered together with non-selective β-blockers. Concomitant administration of xanthine derivatives, diuretics or steroids may lead to severe hypokalaemia; serum potassium levels should be monitored carefully in such cases.



4.6 Pregnancy And Lactation



As with the majority of drugs, salbutamol should not be administered during the first three months of pregnancy. Further use of the product during pregnancy should be restricted to those situations where the expected therapeutic benefit to the mother outweighs any possible risk to the foetus.



In animal studies, administration of salbutamol at very high doses resulted in some harmful effects on the foetus.



Salbutamol is likely to be secreted in breast milk and its effect on breast-fed neonates is not known. Hence, the product should be used in lactation only where the expected benefit to the mother outweighs any potential risk to the neonate.



4.7 Effects On Ability To Drive And Use Machines



None



4.8 Undesirable Effects



Tachycardia, with or without peripheral vasodilatation, may occur rarely.



Cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles) have been reported in association with β2–agonists, usually in susceptible patients.



As with all beta-adrenergic agonists administration of inhaled salbutamol may cause dose-related fine tremors of skeletal muscle.



Headaches have occasionally been reported.



There have been rare reports of muscle cramps.



As with any other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator and Pulvinal Salbutamol should be discontinued straightaway. The patient should be assessed and, if necessary, alternative therapy instituted.



Potentially serious hypokalaemia, which can be potentiated by hypoxia and therefore be worse in acute severe asthma, may result from β2-agonist therapy. Therefore particular caution is advised in acute severe asthma.



As with other β-adrenergic drugs, also with salbutamol there have been rare reports of hyperactivity in children.



Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse have been reported very rarely.



Patients sensitive to the inhalation of a dry powder may occasionally develop throat irritation and cough; this can be minimised by rinsing the mouth after inhalation.



4.9 Overdose



Administration of inhaled salbutamol exceeding the recommended dosage does not generally produce harmful effects; should accidental overdose occur, a cardioselective β-blocking agent should be used, though β-blockers are to be administered with caution in patients with a history of bronchospasm.



As salbutamol overdose may cause hypokalaemia, serum potassium should be monitored.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Salbutamol is a selective β2-stimulant providing marked bronchodilatation, which lasts 4-6 hours. This activity makes this drug particularly suitable for the management of asthma and related diseases characterised by a bronchospastic component.



5.2 Pharmacokinetic Properties



Only 10% of inhaled salbutamol is deposited in the airways and the remainder is retained in the delivery system or is swallowed. The swallowed portion is absorbed through the gut wall, and passed via the liver to the systemic circulation. Salbutamol is readily absorbed from the gastro-intestinal tract and undergoes an extensive presystemic metabolism. The major metabolite is the sulphate conjugate, which is inactive. Up to 80% of the dose administered is recovered in the 24-hour urine, either unchanged or in the form of inactive metabolites. Salbutamol does not appear to be metabolised in the lung where it exerts a local action. In general, inhaled doses are lower than oral doses and blood levels are correspondingly smaller and associated with less severe non-respiratory side effects.



5.3 Preclinical Safety Data



Subacute and chronic toxicity: (inhalation, rat, 6 weeks) no evidence of toxicity or significant histological changes for doses up to 3.3mg/kg over a time of 3 hours daily; (inhalation, rat) doses up to 0.6mg/kg for 6 months did not produce toxic effects; (inhalation, dog, 12 weeks) no signs of toxicity or histological changes were observed following daily administration of 0.15 mg/kg; (oral, rat, 17-18 weeks and 18 months) dose-related (1-50 mg/kg) increase in the incidence of Harderian gland hypertrophy and in the amount of colloid material in the Rathke's pouch area of the pituitary gland. Both glands are involved in the production of melanophore-stimulating hormone (MSH) which has been associated with stimulation of the β-adrenergic receptors.



Reproduction toxicity: (rat) reproduction studies at 0.5



Mutagenicity and carcinogenicity: no mutagenic potential was found in “in vitro” tests and no carcinogenic effects were seen in mice; in rats at very high doses an increase of benign mesovarian leiomyomas was found, as an expression of the excessive β-blocker pharmacological activity.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Lactose monohydrate



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



24 months



6.4 Special Precautions For Storage



Do not store above 30°C. Keep the container tightly closed.



6.5 Nature And Contents Of Container



Multidose dry powder inhaler (Pulvinal consisting of a pale blue mouthpiece, a transparent body-reservoir, a deep blue base containing a desiccant and a blue protective cap.



Pulvinal Salbutamol provides 100 metered doses.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Chiesi Limited



Cheadle Royal Business Park



Highfield



Cheadle



SK8 3GY



United Kingdom



8. Marketing Authorisation Number(S)



PL 08829/0152



9. Date Of First Authorisation/Renewal Of The Authorisation



1st March 2004



10. Date Of Revision Of The Text



22/12/2008



11. LEGAL CATEGORY


POM




Thursday, 2 August 2012

Corvert


Pronunciation: eye-BYOO-tih-lide
Generic Name: Ibutilide
Brand Name: Corvert

Corvert can cause potentially deadly irregular heart rhythms, which can be reversed if treated promptly.





Corvert is used for:

Treating irregular heart rhythms. It may also be used for other conditions as determined by your doctor.


Corvert is an antiarrhythmic. It works by slowing the conduction of the irregular heartbeat throughout the heart, which allows an opportunity for the regular heart rhythm to take over.


Do NOT use Corvert if:


  • you are allergic to any ingredient in Corvert

  • you have prolonged QT interval in electrocardiogram

  • you are taking itraconazole

Contact your doctor or health care provider right away if any of these apply to you.



Before using Corvert:


Some medical conditions may interact with Corvert. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have an irregular or slow heartbeat, congestive heart failure, other heart problems, or low levels of magnesium or potassium

Some MEDICINES MAY INTERACT with Corvert. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Arsenic, cisapride, itraconazole, ketolides (eg, telithromycin), macrolides (eg, erythromycin), phenothiazines (eg, promethazine), and other medications that prolong the QT interval because they may increase the risk abnormal heart rhythms, including fatal heart rhythms, such as torsades de pointes

This may not be a complete list of all interactions that may occur. Ask your health care provider if Corvert may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Corvert:


Use Corvert as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Corvert is administered as an infusion at the hospital.

  • If Corvert contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.

  • Keep this product, as well as syringes and needles, out of the reach of children and away from pets. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.

  • If you miss a dose of Corvert, contact your doctor immediately.

Ask your health care provider any questions you may have about how to use Corvert.



Important safety information:


  • Corvert may cause dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Corvert. Using Corvert alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

  • Corvert is not recommended for use in CHILDREN. Safety and effectiveness have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, discuss with your doctor the benefits and risks of using Corvert during pregnancy. It is unknown if Corvert is excreted in breast milk. Do not breast-feed while taking Corvert.


Possible side effects of Corvert:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dizziness; headache; nausea; rapid heartbeat.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; fainting; fast or slow heartbeat; heart block; heart failure; shortness of breath; swelling of feet or ankles; worsening of heart rhythm problems.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Corvert side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include abnormal heart rhythms; heart block.


Proper storage of Corvert:

Corvert is usually handled and stored by a health care provider. If you are using Corvert at home, store Corvert as directed by your pharmacist or health care provider.


General information:


  • If you have any questions about Corvert, please talk with your doctor, pharmacist, or other health care provider.

  • Corvert is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Corvert. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Corvert resources


  • Corvert Side Effects (in more detail)
  • Corvert Use in Pregnancy & Breastfeeding
  • Corvert Drug Interactions
  • Corvert Support Group
  • 0 Reviews for Corvert - Add your own review/rating


  • Corvert Prescribing Information (FDA)

  • Corvert Concise Consumer Information (Cerner Multum)

  • Corvert Monograph (AHFS DI)



Compare Corvert with other medications


  • Atrial Fibrillation
  • Atrial Flutter

Lamisil Topical


Generic Name: terbinafine topical (ter BIN a feen TOP i kal)

Brand Names: Athlete's Foot Cream, LamISIL AT, LamISIL AT Athletes Foot, LamISIL AT Jock Itch, LamISIL Topical


What is Lamisil Topical (terbinafine topical)?

Terbinafine is an antifungal medication. Terbinafine topical prevents fungus from growing on the skin.


Terbinafine topical (for the skin) is used to treat skin infections such as athlete's foot, jock itch, and ringworm infections.


Terbinafine topical may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Lamisil Topical (terbinafine topical)?


Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to.


Avoid getting this medication in your mouth or eyes.

What should I discuss with my healthcare provider before using Lamisil Topical (terbinafine topical)?


You should not use this medication if you are allergic to it. It is not known whether terbinafine topical will be harmful to an unborn baby. Do not use terbinafine topical without first talking to your doctor if you are pregnant. It is not known whether terbinafine topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use Lamisil Topical (terbinafine topical)?


Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended. Follow the directions on your prescription label.


Wash your hands before and after using this medication.

Clean and dry the affected area. Apply the medication as directed.


Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.


For best results, keep using the medication as directed. Talk with your doctor if your symptoms do not improve after a few weeks of treatment.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to.


Store terbinafine topical at room temperature away from moisture and heat.

What happens if I miss a dose?


Apply the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to use the medicine and skip the missed dose. Do not apply extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of terbinafine topical is not likely to cause life-threatening symptoms.


What should I avoid while using Lamisil Topical (terbinafine topical)?


Avoid getting this medication in your mouth or eyes. If it does get into any of these areas, rinse with water.

Avoid using other medications on the areas you treat with terbinafine topical unless your doctor has told you to.


Avoid wearing tight-fitting, synthetic clothing that doesn't allow air circulation. Wear loose-fitting clothing made of cotton and other natural fibers until your infection is healed.


Lamisil Topical (terbinafine topical) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using terbinafine topical and call your doctor at once if you have a serious side effect such as severe blistering, itching, redness, peeling, dryness, or irritation of the skin.

Less serious side effects are more likely, and you may have none at all.


This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Lamisil Topical (terbinafine topical)?


It is not likely that other drugs you take orally or inject will have an effect on topically applied terbinafine topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Lamisil Topical resources


  • Lamisil Topical Side Effects (in more detail)
  • Lamisil Topical Use in Pregnancy & Breastfeeding
  • Lamisil Topical Support Group
  • 0 Reviews for Lamisil Topical - Add your own review/rating


  • Lamisil AT Prescribing Information (FDA)

  • Lamisil AT Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Lamisil AT Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Lamisil AT Jock Itch Prescribing Information (FDA)



Compare Lamisil Topical with other medications


  • Tinea Versicolor


Where can I get more information?


  • Your pharmacist has additional information about terbinafine topical written for health professionals that you may read.

See also: Lamisil Topical side effects (in more detail)


Sunday, 29 July 2012

Indapamide CF




Indapamide CF may be available in the countries listed below.


Ingredient matches for Indapamide CF



Indapamide

Indapamide is reported as an ingredient of Indapamide CF in the following countries:


  • Netherlands

International Drug Name Search